Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Consumer/Patient Experience Special Feature: Return on experience

In healthcare, we are fortunate to have access to code that analyzes data and provides us with customer insights. As marketers, we can now understand these individual customers better than ever before. We know what we need and want to do when it comes to reaching them. But what does all that power and possibility do for them?

Read More »

HBA Global presents Virtual Professionals: Visibility & Trajectory in a Virtual Career (Series Purchase – 3 Webinars)

Are you in sales, working out in the field or working remotely or virtually, away from the home office? Then these webinars are for you! Join the HBA for a three-part webinar series that takes on core challenges that virtual workers – both field-based and remote – face in their careers: gaining and improving visibility; career planning; and building relationships with mentors, sponsors and coaches.

Read More »

Teva Pharm to pay Oklahoma $85 million to settle opioid claims

Teva Pharmaceutical agreed to pay an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that the world’s largest generic manufacturer and other drugmakers helped fuel the U.S. opioid epidemic.

Read More »

Gilead Sciences Cuts 150 Sales Jobs

The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of the company’s sales team, according to reports.

Read More »

Agenda 2019 Special Feature: Hungry AIs

Artificial intelligence generated plenty of chatter amongst the pharma marketing intelligentsia in 2018. Will 2019 be the year when the industry fully embraces it as more than just a tactic?

Read More »

Medical affairs in the digital age

Evidenced by the move to measure and reimburse providers based on the quality, as opposed to the quantity, of care delivered, the healthcare industry is shifting from a fee-for-service to an outcomes or value-based model.

Read More »

J&J, U.S. states settle hip implant claims for $120 million

Johnson & Johnson and the company’s DePuy Orthopaedics unit have agreed to pay $120 million to resolve deceptive marketing claims by several U.S. states over the company’s metal-on-metal hip implants.

Read More »

Ad-ventures in Marketing XI

For the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.

Read More »

Maryland charges Insys with engaging in deceptive opioid scheme

Maryland charged Insys Therapeutics Inc. with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients.

Read More »

Medtronic settles states’ probe into Infuse marketing for $12 million

Medtronic Plc agreed to pay $12 million to resolve claims that the company engaged in a deceptive marketing strategy to promote its Infuse bone graft product used in spinal surgery, the Massachusetts attorney general said.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom